Lyra Therapeutics Stock Today
| LYRA Stock | USD 24.28 1.05 4.15% |
PerformanceOK
| Odds Of DistressHigh
|
Lyra Therapeutics is trading at 24.28 as of the 7th of June 2025, a 4.15 percent decrease since the beginning of the trading day. The stock's open price was 25.33. Lyra Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 8th of May 2025 and ending today, the 7th of June 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 1st of May 2020 | Category Healthcare | Classification Health Care |
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. Lyra Therapeutics, Inc. The company has 1.33 M outstanding shares of which 7.33 M shares are now shorted by private and institutional investors with about 1.19 trading days to cover. More on Lyra Therapeutics
Lyra Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Maria Palasis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsLyra Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lyra Therapeutics' financial leverage. It provides some insight into what part of Lyra Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lyra Therapeutics (LYRA) is traded on NASDAQ Exchange in USA. It is located in 480 Arsenal Way, Watertown, MA, United States, 02472 and employs 30 people. Lyra Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 32.18 M. Lyra Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.33 M outstanding shares of which 7.33 M shares are now shorted by private and institutional investors with about 1.19 trading days to cover.
Lyra Therapeutics currently holds about 120.67 M in cash with (70.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.79.
Check Lyra Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Lyra Therapeutics is $32.18 Million. 30% of Lyra Therapeutics outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Lyra Ownership Details
Lyra Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Northern Trust Corp | 2024-12-31 | 286.3 K | |
| Bnp Paribas Arbitrage, Sa | 2025-03-31 | 242.5 K | |
| Boothbay Fund Management, Llc | 2025-03-31 | 234 K | |
| Two Sigma Investments Llc | 2025-03-31 | 193.1 K | |
| New York State Common Retirement Fund | 2025-03-31 | 154.8 K | |
| Charles Schwab Investment Management Inc | 2025-03-31 | 111.6 K | |
| Susquehanna International Group, Llp | 2024-12-31 | 103.4 K | |
| Rhumbline Advisers | 2025-03-31 | 87.7 K | |
| Bank Of New York Mellon Corp | 2025-03-31 | 71.6 K | |
| Perceptive Advisors Llc | 2025-03-31 | 12.8 M | |
| Blackrock Inc | 2025-03-31 | 3 M |
Lyra Therapeutics Historical Income Statement
Lyra Stock Against Markets
Lyra Therapeutics Corporate Management
| Dr Roberts | CoFounder | Profile | |
| Corinne Noyes | Senior Development | Profile | |
| Donald MBA | Advisor | Profile | |
| Gloria Cosgrove | Senior Quality | Profile | |
| Ellen Cavaleri | Senior Communications | Profile | |
| Richard MD | Chief Officer | Profile | |
| Ronan JD | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lyra Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (65.99) | Revenue Per Share | Quarterly Revenue Growth (0.66) | Return On Assets | Return On Equity |
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.